Forendo Pharma Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 26
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $954M
Latest Deal Amount

Forendo Pharma General Information

Description

Developer of therapeutic drugs designed to assist in the treatment of women's health indications. The company's drugs are competent in tissue-specific hormone mechanisms for the treatment of broader gynecological conditions like endometriotic lesions and polycystic ovarian syndrome, enabling medical professionals to improve the treatment of female urological conditions efficiently.

Contact Information

Website
www.forendo.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Organon & Co.
Primary Office
  • Itäinen Pitkäkatu 4 B
  • 20520 Turku
  • Finland
+358 040 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Forendo Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 13-Dec-2021 $954M 000.00 00000 Completed Clinical Trials - Phase 1
7. Later Stage VC 03-Dec-2019 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
6. Later Stage VC 17-Jul-2019 00.000 000.00 000.00 Completed Clinical Trials - Phase 1
5. Later Stage VC 05-Sep-2018 00.000 000.00 0000 Completed Clinical Trials - Phase 1
4. Debt - General 19-Mar-2018 00.00 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A) 23-Oct-2014 000.00 000.00 000.00 Completed Startup
2. Debt - General 01-Jan-2014 $4.59M Completed Startup
1. Seed Round 01-Jan-2013 $4.59M $4.59M 00.000 Completed Startup
To view Forendo Pharma’s complete valuation and funding history, request access »

Forendo Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B1 shares 0,000 00000.00 00000.00 00 00000.00 0.000
B1 shares 0,000 00000.00 00000.00 00 00000.00 00.000
B1 shares 0,000 00000.0 00000.0 00 00000.0 0.000
Series B 2,083 $3340.7 $3340.7 1x $3340.7 13.84%
Series B 2,435 $1587.65 $1587.65 1x $1587.65 13.84%
To view Forendo Pharma’s complete cap table history, request access »

Forendo Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic drugs designed to assist in the treatment of women's health indications. The company's drugs ar
Drug Discovery
Turku, Finland
26 As of 2021
000.00
0000 0000-00-00
000000&0 000.00

000000

oluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pr
0000000000000
Geneva, Switzerland
00 As of 0000
00000
00000000

00000000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nos
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Forendo Pharma Competitors (67)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ObsEva Formerly VC-backed Geneva, Switzerland 00 00000 00000000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed Waltham, MA 0 00000 000000000 00000
000000000 Formerly VC-backed Oxford, United Kingdom 00 00000 00000000 00000
You’re viewing 5 of 67 competitors. Get the full list »

Forendo Pharma Patents

Forendo Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3122049-A1 Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 Pending 05-Dec-2018 00000000000
AU-2019393005-A1 Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 Pending 05-Dec-2018 00000000000
EP-3891167-A1 Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 Pending 05-Dec-2018 00000000000
AU-2018279205-A1 15.beta.-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases Granted 08-Jun-2017 0000000000
CA-3066196-A1 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydro-genases Pending 08-Jun-2017 C07J43/003
To view Forendo Pharma’s complete patent history, request access »

Forendo Pharma Executive Team (4)

Name Title Board Seat Contact Info
Risto Lammintausta Ph.D Co-Founder, Chief Executive Officer and Board Member
Pasi Koskimies Ph.D Co-Founder and Project Director
You’re viewing 2 of 4 executive team members. Get the full list »

Forendo Pharma Board Members (14)

Name Representing Role Since
Risto Lammintausta Ph.D Forendo Pharma Co-Founder, Chief Executive Officer and Board Member 000 0000
You’re viewing 1 of 14 board members. Get the full list »

Forendo Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Forendo Pharma Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Finnvera Venture Capital Minority 000 0000 000000 0
Innovestor Venture Capital Minority 000 0000 000000 0
Karolinska Development Venture Capital Minority 000 0000 000000 0
M Ventures Corporate Venture Capital Minority 000 0000 000000 0
Novartis Corporation Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »